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Introduction: The present study investigated the incidence, management and outcome of Gastroin-
testinal Stromal Tumors (GIST) in Qatar. Methods: A retrospective review of all GIST patients admitted
between 1995 and 2012 was conducted. Patients' demographics, clinical presentation, tumor charac-
teristics, radiological, pathological and immunohistochemical ﬁndings, surgical procedures, recurrence
and mortality were recorded. Results: A total of 48 GIST patients were identiﬁed. Stomach (56%) and
small intestine (27%) were the most common sites of tumor. The majority of cases (n ¼ 27) had tumor
size >5 cm, 31 cases had primary and 15 cases had locally advanced tumor. Patients were stratiﬁed as
high, intermediate, and low risk (43.8%, 18.8% and 37.5%, respectively). Almost all the cases were sur-
gically managed and 94% were completely resectable. Robotic partial resection was performed in 4 cases
and 5 cases underwent laparoscopic resection. Chemotherapy was initiated in half of patients. During
follow up (average 37.5 months), 33 patients showed complete recovery, 7 had recurrent or metastatic
disease and 2 died due to liver metastasis. Conclusion: The incidence of GIST in Qatar is apparently low.
Surgical resection is the preferred choice of treatment; however, robotic and laparoscopic resections are
feasible and safe approaches in some cases.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.IST; platelet derived growth
; magnetic resonance imag-
ical Corporation, HMC; high
; Armed Forces Institute of
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by Elsevier Ltd. All rights reserved1. Introduction
Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal neoplasms, accounted for 1e3% of all gastrointestinal
malignancies, which arise anywhere within the gastrointestinal
tract [1]. GISTs originate from the stomach are most common fol-
lowed by small intestinal origin. However, in rare cases, it may be
seen in intra-abdominal sites such as the omentum, mesentery and
retroperitoneum. Earlier, GISTs were considered as variants of
smooth muscle tumors. With the advancement of molecular.
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from interstitial cells of Cajal or their stem cell precursors [2e4]. c-
KIT gene mutation occurs in vast majority of GIST cases (more than
80% of GISTs) followed by platelet derived growth factor receptor a
(PDGFRA) mutations. c-KIT and PDGFRA genes are located in the
fourth chromosome in humans [5]. CD117, a protein encoded by the
c-KIT gene, is an important marker in the diagnosis of GIST. Other
markers used are; CD34, vimentin, keratin, smooth muscle actin
(SMA) and S100 [4]. The risk of GIST is increasing in people who
have inherited the mutation and in some instances GISTs can be
found in several members of the same family [6].
GIST can be asymptomatic and incidental ﬁnding. Depending on
the size and site, the symptoms of GIST vary, which include
abdominal pain and bleeding. Diagnostic work up consists of
endoscopy with ultrasonography and cross-sectional imaging
techniques such as computed tomography (CT) and/or magnetic
resonance imaging (MRI). Several criteria for risk stratiﬁcation exist
such as Fletcher's criteria; the ﬁrst attempt in assessing the ma-
lignant potential of GIST. These criteria are based on the size of
tumor and mitotic activity [2,7]. GISTs greater than 2 cm in diam-
eter are often surgically resectable, whereas less than 2 cm in
diameter are closely monitored for metastasis. Surgical resection
remains the established mode of effective treatment for GISTs.
However, the use of oral inhibitors likes imatinib that targeting
mutations are indicated in patients with inoperable or metastatic
disease [8]. Other approaches include photodynamic therapy (PDT)
that utilizes reactive oxygen species to kill tumor cells [9].
The incidence and prevalence of GISTs in Qatar remain under-
studied. The present study aims at reﬂecting the epidemiology and
management of GIST in Qatar.
2. Patients and methods
A retrospective analysis was conducted for all the patients who
were admitted to the surgery department at Hamad Medical Cor-
poration (HMC) in Qatar, between 1995 and 2012. Patients with a
conﬁrmed diagnosis of GIST were included in the study. The
collected data included patients' gender, nationality, clinical pre-
sentations, radiological investigations, laboratory ﬁndings, tumor
characteristics, pathological ﬁndings, surgical procedures, intra and
post-operative complications. Investigations included X-ray, ultra-
sonography, CT scan, barium study, MRI and endoscopy. Immuno-
histochemical analysis was performed using markers such as
CD117, CD34, SMA and S-100 protein. Mitotic rate was measured
using high power ﬁelds (HPF). Post-operative complications,
recurrence and mortality data were recorded during the follow up
period. This study was approved by the medical research center at
HMC, Doha, Qatar (IRB# 13269/13). Data were reported as per-
centages, mean ± standard deviation, and median and range, when
applicable. Chi Square test was used to compare the risk between
(males and females), (young and old age), and (Arabs and Asians)
patients. A 2-tailed p value of <0.05 was considered signiﬁcant.
Data analysis was carried out using the statistical package for social
sciences version 18 (SPSS Inc, Illinois).
3. Results
This study included 48 GIST patients; 31 males and 17 females.
Out of these, 12 patients were Qataris, 11 were non-Qatari Arabs
and 23 were Asians. Mean age of the patients at diagnosis was
48.4 ± 13.7 years (ranged from 23 to 77 years). The most presented
clinical symptoms were abdominal pain (85.4%), vomiting (52%)
and blood in stool (54.2%). Bowel obstruction was seen in 3 pa-
tients; one of them had gastric volvulus and hiatus hernia. One
patient presented with urinary retention (rectal mass invading theprostate). Two patients were found to have ruptured small bowel
tumor at presentation (one had trafﬁc-related trauma and one
presented with abdominal pain and thought to have intra-
abdominal abscess) Most common site of tumor was stomach
(56%) followed by small intestine (27%) (Fig. 1).
Fig. 2 shows radiologic and intraoperative ﬁndings for one of our
cases with large gastric GIST. Tumors originated from duodenum in
4 patients, from colon in 2 patients and in rectum in 2 patients.
Maximum size of the tumor was equal to or less than 2 cm only in 5
patients whereas greater than 5 cm in 27 patients. GIST was
localized to primary organ site in most of the cases (n ¼ 31) and
locally advanced in 15 patients. Distant metastasis at evaluation
was found in 15% of the patients. Table 1 shows the demographics
and clinical presentation of GIST patients.
Patients were stratiﬁed as high, intermediate, and low risk
(43.8%, 18.8% and 37.5%, respectively). Fig. 3 shows the comparison
between females and males, young (<40 years) and older (>40
years), and Arabs and Asians in regard to the risk stratiﬁcation.
All the cases were surgically managed; 94% were completely
resectable and only 3 patients found unresectable. Four patients
underwent robotic partial resection for posterior wall gastric tu-
mors. Five cases underwent laparoscopic resection; 3 of themwere
discovered incidentally during Sleeve gastrectomy. Chemotherapy
was initiated in half of the patients and radiation therapy was
indicated in one case (very early in the study). The mean hospital
length of stay was 9.5 days, ranging from one to 45 days. Patients
were followed up for 37.5 (1e186) months. Complications such as
bleeding were reported in 3 cases and infection in 2 patients.
During the follow up period, 33 patients were alive without evi-
dence of recurrence, 7 were alive with recurrent or metastatic
disease and 6 patients left country after surgery. Two patients died
during the follow up period; one had 17 cm gastric mass underwent
3 surgical interventions and died due to recurrent liver metastasis,
whereas the second one presented with 13 cm rectal mass with
liver metastasis underwent 5 surgical interventions. Table 2 shows
the management and outcome. Fig. 4 shows the study overview
(site of origin, diagnosis, management and outcomes of GISTs).
4. Discussion
The present study describes for the ﬁrst time in Qatar the fre-
quency, clinical presentation, management and outcomes of GIST.
We reported 48 cases over 17 years. Nearly 50% of cases were from
South Asians, whereas 25% were nationals (Qataris). Qatar is an
Arab Middle Eastern country with small population that increased
from 501,000 in 1995 to 1,448,479 in 2008 and 1,832,903 in 2012.
Fig. 5 shows the incidence of GIST in Qatar per year. The highest
incidence rate was shown in 2008 (0.55 per 100,000) and 54% of
cases were diagnosed in the last third of the study period. This
ﬁnding may reﬂect the advancement of the modality of diagnosis
after 2006. Various epidemiological studies showed the incidence
of GIST as 5e20 per million of the population [4,10,11]. The
Taiwanese cancer registry-based study reported more than 5% in-
crease in incidence of GIST in ten years [4], likely reﬂects the ad-
vancements in diagnosis of the disease. A 30-year study in Japan
also showed similar trend of signiﬁcant increase in the GIST inci-
dence during the last decade [12]. However, it is difﬁcult to
compare the incidence rates in different countries due to the dif-
ferences in study time periods and the lack of application of KIT
immunohistochemical conﬁrmation in some studies.
GIST can be presented at any age regardless the gender. There is
no good information regarding any association of GIST with
geographic location, ethnicity or race. In our study, GIST was
equally diagnosed in Arabs and Asians with a mean age of 48 years
and male predominance. Experience from an Italian group showed
Fig. 2. A: CT scan of large gastric GIST tumor. B: Intraoperative large gastric anterior
wall GIST tumor with omentum wrapped around it.
Fig. 1. Site of GIST based on origin and extension .
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males [13]. Sorour et al. [1] reported the mean age of patients at
diagnosis of GIST was nearly 50 years, whereas Miettinen et al. [14]
revealed GISTs occurs rarely below 40 years and very unusual in
children. Our report shows that one third of cases (16 patients)
were diagnosed in patients 40 years old. Wang et al. [10] reported
high incidence of GIST between 50 and 59 years of age. In a Middle
East population, GISToccurred inmales over 40 years of age inmost
of the cases [15]. A slight male predominance in GIST incidence was
reported in Taiwanese study but the Chinese survey showed equal
rates of incidence similar to the Italian hospital study [4,10,13]. The
Taiwanese data demonstrated younger age and female sex as in-
dependent predictors of better survival.
Although 10e30% of patients are asymptomatic, GIST associated
symptoms varies with the site and size of the lesion. The common
site for GIST reported in almost all studies is stomach, accounted
nearly 41% in a Jordanian study population [15], and more than half
of GIST cases in Saudi Arabian and Egyptian studies [1,16]. More-
over, one in ﬁve GIST patients in Saudi Arabian study had tumors in
the small bowel [16]. Nearly half of the cases in the Egyptian study
presented with gastrointestinal bleeding; followed by symptoms
such as intestinal obstruction in nearly 30%, intraperitoneal hem-
orrhage in 15%, and rupture and peritonitis in 8% [1]. Our study is
also in line with the previous studies regarding the site of tumor;
56% of patients had tumors in stomach followed by 27% of small
bowel origin. Abdominal pain was present in most of the patients
(85%). Blood in stool and vomiting was reported in more than half
of the patients. However, bowel obstruction was seen in less than
10% of patients.
Tumor size is crucial in the progression of the disease. The
Chinese epidemiological study recorded mean diameter of 5.78 cm
(0.3e25 cm) [10]. An Egyptian study on gastric stromal tumors
which included 16 GIST patients reported tumor sizes between 8.4
and 20 cm [17]. In the present study, the median tumor size was
8 cm ranging from 0.4 to 18 cm. Our study also shows 62% of the
cases are with tumor size greater than 5 cm.
GIST risk stratiﬁcation systems are mainly based on tumor size
that leads to assessment of the malignancy. The National Institutes
of Health (NIH) consensus criteria, also known as Fletcher's criteria,
were the ﬁrst risk stratiﬁcation system developed [18]. Eight
prognostic categories based on tumor size and mitotic activity with
four subdivisions of risk groups was used to assess the malignant
potential. The 5 cm size was the cut-off value to deﬁne low and
non-low risk tumors [19]. Notably, 62% of the patients in our study
fall into the non-low risk category. Following the Fletcher et al.
criteria; 33% are at high risk, 31% at intermediate risk, 26% at low
risk and 10% at very low risk categories. The present study shows
that high risk was signiﬁcantly evident in Arabs in comparison to
Asians (p ¼ 0.03), and in young in comparison to old patients
(p ¼ 0.04), whereas gender did not play a signiﬁcant role in the risk
stratiﬁcation.
Unlike Fletcher's criteria; Armed Forces Institute of Pathology
(AFIP) criteria, known as Miettinen's criteria, considers the
anatomic site of the tumor and included the risk group of ‘benign
tumors’ with no risk of malignancy [14]. Gastric GISTs 10 cm and
5 mitoses per 50 HPFs possess a low risk for metastasis, whereas
>5 per 50 HPFs and >5 cm in diameter have a high risk for
metastasis. On the other hand, all intestinal GISTs >5 cm regardless
mitotic rate have at least moderate risk for metastases, and all >5
mitoses per 50 HPFs have a high risk for metastases [14,18]. Table 3
shows comparison of various stratiﬁcation systems used.
In 2009, Gold et al. [20] developed a nomogram to predict
recurrence-free survival after surgery in GIST patients. The risk of
tumor progression was estimated using a point system based on
tumor site (gastric, small intestine, colon/rectum, extra-
Table 1
Demographics and clinical presentation of GIST patients (n ¼ 48).
Age (mean ± SD) 48.4 ± 13.7 Histological type
Males 31 (64.6%) Spindle cell type 31 (67.4%)
Females 17 (35.4%) Epithelioid type 7 (15.2%)
Nationality Mixed type 4 (8.7%)
Qatari 12 (25%) Unspeciﬁed 10 (21.3%)
Arab non-Qatari 11 (22.9%) Immunohistochemical analysis
Asian 23 (47.9%) CD117 34 (85%)
Others 2 (4.2%) CD34 34 (85%)
Neuroﬁbromatosis 0 (0%) Smooth-Muscle
Actin (SMA)
13 (32.5%)
Familial urticaria
pigmentosa
0 (0%) S-100 protein 2 (5%)
Maximum size of
tumor (cm) (median,
range)
8 (0.4e18)
Familial GIST 0 (0%) Tumor size (cm)
Clinical presentation 2 5 (11.1%)
Abdominal pain 41 (85.4%) >2e5 13 (28.9%)
Vomiting 25 (52%) >5e10 16 (35.6%)
Blood in stool 26 (54.2%) >10 11 (24.4%)
Fatigue 9 (19%) Mitotic count (High Power ﬁelds; HPF)
Bowel obstruction 3 (6.3%)
Urinary retention 1 (2.1%) 5 32 (74.4%)
Radiological investigations >5 11 (25.6%)
X-ray 24 (50%) Tumor necrosis 16 (36.4%)
Ultrasonography 18 (37.5%) Risk stratiﬁcation
Computed
tomography
41 (85.4%) High 21 (43.8%)
Barium study 7 (15%) Intermediate 9 (18.8%)
MRI 4 (8.3%) Low 18 (37.5%)
Endoscopy 24 (50%)
H. Al-Thani et al. / International Journal of Surgery 12 (2014) 1127e11331130gastrointestinal), size and mitotic activity. Further studies pointed
out additional independent prognostic factors such as primary tu-
mor location, sex, and ‘clinically malignant factors’ such as perito-
neal dissemination, invasion, metastasis and tumor rupture
[18,20e23]. Joensuu conﬁrmed that tumor rupture leads to
increased risk of recurrence and also pointed out the fact that
gastric GISTs have a lower risk of recurrence than non-gastric tu-
mors of the same size andmitotic count [23]. As per the revised NIH
system proposed by Joensuu, all gastric GISTs found >5 mitoses perFig. 3. Shows (upper panel) the comparison between females and males, young (<40 ye
stratiﬁcation.50 HPFs and with >10 cm tumor size are at high risk, found in 14%
of gastric GIST cases in our study. Meanwhile, the criteria for non-
gastric GISTs are different, and the proportion of high risk cases
will be higher for non-gastric tumors. Woodall et al. [24] proposed
a clinical staging system for GISTs and tumor size of 70mmwas the
cut-off point for differentiating clinical behavior in GISTs. This was
found effective when compared to tested values of 2 cm, 5 cm and
10 cm. However, further studies are required to validate this sys-
tem. Table 4 shows the GIST risk stratiﬁcation in the present study
following different criteria.
Non-gastric tumors accounted for nearly 90% of the tumors
metastasized in the study [11]. In Saudi Arabian GIST study, nearly
41% were at high risk, 35% at intermediate, 8% at low risk, and one
case was very low risk for metastasis [16]. The Jordan based study
revealed, out of 27 GIST cases; 64.3% were high risks, 9.5% inter-
mediate risk, 14.3% low risk, and 4.8% as very low risk [15]. Our
study showed 43.8% were at high risk followed by 18.8% interme-
diate and 37.5% low risk. In the present study, nearly 44% of GIST
patients had non-gastric tumors and more than half (55%) of these
are at high risk according to Fletcher's criteria. Notably, 80% of non-
gastric GISTs fall in high or intermediate risk which is consistent
with previous studies showing high risk of progression for non-
gastric tumors.
Surgical resection is the effective and established mode of
treatment for GISTs. Neoplastic mass and gastric wall excision with
sufﬁcient surgical margins can be achieved with different surgical
techniques which depend on the tumor dimension and localization
[25]. In our study, 65% of the GISTs were localized to the primary
organ site and 15% were locally advanced. Small GISTs are usually
dealt with wedge resection, whereas gastric resection and total
gastrectomy is often conducted in cases of large GISTs localized
near the cardia. The National Comprehensive Cancer Network
(NCCN) [26] suggested laparoscopic techniques should be used only
in tumors less than 2 cm in size. However, there are some reports
indicating laparoscopy was effective and safe in removing larger
GISTs but inadequate resectionmargins or tumor spillage leading to
disease progression, recurrence and poor survival remain as main
issues [27]. In our study, 5 cases with non-posterior wall gastric
tumors underwent laparoscopic resection. Three cases were postedars) and older (>40 years), and (lower panel) Arabs and Asians in regard to the risk
Table 2
Management and outcome of GIST cases.
Management
Completely resectable 45 (94%)
Resectable surgical margins 9 (20%)
Unresectable 3 (6.3%)
Laparoscopic resection 5 (10.4%)
Robotic resection 4 (8.3%)
Chemotherapy 24 (50%)
Radiation therapy 1 (2%)
Blood transfusion units (within 24 h post-operation) 2 (1e4)
Hemoglobin (before operation) 9.7 ± 2
Hospital length of stay (days) 9.5 (1e45)
Follow up period (months) 37.5 (1e186)
Complications
Bleeding 3 (6.3%)
Infection 2 (4.2%)
Deep vein thrombosis 0
Outcome
Alive without recurrence/metastasis 33 (68.5%)
Alive with recurrent/metastatic disease 7 (15%)
Died 2 (4%)
Lost to follow up after surgery 6 (12.5%)
1 1 1
2 2 2
1
0
2
1
4
5
1
8
7
2
4
4
Fig. 5. Incidence of GIST cases per year in Qatar.
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anastomosis (GIA) staple, and found to have GISTs localized to the
greater curvature of the stomach. The 4th case had anterior wall
stomach tumor and wedge resection was done with linear staple.
The 5th case had distal stomach tumor underwent distal gastrec-
tomy and gastrojejunal anastomosis with laparoscopic gastroin-
testinal anastomosis stapler. Moreover, we have performed robotic
resection for 4 posterior wall gastric tumors. We selected roboticFig. 4. Study oresection for the posterior wall tumor because the robotic arms
gave us the opportunity to rotate the stomach organoaxial. This
enables us to expose the posterior wall and the lesion. Resection of
the tumor and a cuff of normal stomach using an electrocautery
hook were performed in 3 cases, whereas ultrasonic coagulation
shears (Harmonic, Johnson & Johnson) was done in one. The gas-
trotomy was closed by intracorporeal suturing in two layers. All the
specimens were removed using specimen retrieval bag.
Desiderio et al. [27] demonstrated in 5 cases that robotic
resection addresses the oncologic safety issues and advantageous
being minimally invasive and provides favorable perioperative
outcomes when compared to open and laparoscopic surgery. In our
study, 94% of the cases were completely resectable, 20% were with
resectable surgical margins and less than 10% were unresectable.verview.
Table 3
Comparison of different stratiﬁcation systems.
Tumor
size
(cm)
Mitoses/
50HPF
Fletcher's [19]
criteria (NIH)-
all sites
Miettinen's
[14] criteria
(AFIP)-gastric
Joensuu [23]
(revised
NIH)-gastric
Joensuu [23]
(revised NIH)-
non-gastric
2 5 Very low Benign Very low Very low
>2e5 5 Low Very low Low Low
>5e10 5 Intermediate Low Intermediate High
>10 5 High Intermediate High High
2 >5 Intermediate/
High
Low Intermediate/
High
Intermediate/
High
>2e5 >5 Intermediate/
High
Intermediate Intermediate/
High
High
>5e10 >5 High High High High
>10 >5 High High High High
Table 4
Risk stratiﬁcation of GIST patients in the present study.
Risk
categories
Fletcher's [19]
criteria (NIH)-
all sites
Miettinen's [14]
criteria (AFIP)-
gastric
Joensuu [19]
(revised NIH)-
gastric
Joensuu [23]
(revised NIH)-
non-gastric
Benigna N/A 4/22 (18%) N/A N/A
Very low 4/42 (10%) 7/22 (32%) 4/22 (18%) 0
Low 11/42 (26%) 8/22 (36%) 7/22 (32%) 4/20 (20%)
Intermediate 13/42 (31%) 1/22 (5%) 8/22 (36%) 5/20 (25%)
High 14/42 (33%) 2/22 (9%) 3/22 (14%) 11/20 (55%)
N/A ¼ not applicable.
a Only proposed by Miettinen's criteria (AFIP).
H. Al-Thani et al. / International Journal of Surgery 12 (2014) 1127e11331132The primary goal of the surgery was to remove the tumor
completely with avoiding tumor rupture. Presence of residual tu-
mor is associated with early recurrence and short survival. Sorour
et al. [1] reported 3 and 5 years disease free survival for all GIST
patients as 73.2% and 64.5% respectively.
Tumor sizes have a signiﬁcant impact on overall survival. Sur-
gery among low and intermediate-risk patients generally produces
good outcomes, whereas high-risk tumors often recur after resec-
tion. Moreover, secondary surgery results in poor outcomes.
The mean hospital length of stay in our study was 9.5 days,
ranging from one to 45 days. Patient outcomes in our study were
recorded during the follow up of patients. Seven percent of the
patients lost to follow up. Median follow up in our study was 37.5
months ranges from 1 to 186 months. More than three quarter of
our patient population were alive without any disease during the
follow up period. Two out of 42 patients died and 7 patients were
alive with recurrent or metastatic disease. Only one among these
patients was having gastric GIST and had metastasis in liver. For
non-gastric GIST patients, all died or alive with recurrent or
metastasis were at high risks as per revised NIH system for non-
gastric GISTs.
One of our expired patients presented with liver metastasis, and
had three surgeries in total including for recurrence in the duration
of tenyears. Themaximum tumor size in this patient was 17 cm and
was at high risk according to all risk stratiﬁcation systems discussed
here. Our study is in line with the previous studies that pointed out
liver as the common site for metastasis. The retrospective analysis
of 200 GIST patients underwent surgery, revealed that 47% was
already metastatic at diagnosis, and the most frequent sites were
the liver (50%) and peritoneum (20%) [28]. Sorour et al. [1] found,
one patient had liver metastasis and 5 had peritoneal metastasis, in
their series of 92 patients.
Unresectable patients normally have short survival and frequent
recurrence. Studies have shown that median survival among
unresectable GIST patients was around 12months (ranges from 2 to
20 months) [1]. The only three unresectable cases in our study (2rectal and 1 gastric) were followed up for median 23 months
(18e45 months), two were found alive with metastasis and one
died. Nearly 70% of the patients who died or alive with morbidity
had tumors greater than 5 cm in size. Seven out of 14 patients who
classiﬁed as high risk group according to Fletcher's criteria found
died or alive with recurrent or metastatic disease. Although the
number of GISTs is not high, the different treatment modalities we
followed will increase the learning curve in this small country and
encourage surgeons to pay more attention for the appropriate
diagnostic and grading tools.
5. Conclusion
The incidence of GIST in Qatar is apparently low. Surgical
resection is the preferred choice of treatment; however, robotic and
laparoscopic resections are feasible and safe approaches in some
cases.
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